Latest Industry Insights

The biotech/genetic engineering company Colossal – co-founded in 2021 by renowned geneticist Professor George Church and serial entrepreneur Ben Lamm – announced it has begun a de-extinction project of the thylacine – an Australian marsupial commonly referred to as the “Tasmanian tiger”. Technology Networks interviewed the team to learn more.

Technology Networks recently had the pleasure of speaking to Dr. Philip Empey, to learn more about the Pharmacogenomics Center for Excellence and how it is working to prove the clinical utility of predictive PGx testing.

Technology Networks spoke to Dr. Cenk Sumen, chief scientific officer of MaxCyte, about their pioneering cell engineering platform.

To learn more about new technologies being developed for drug discovery and cell therapy, Technology Networks spoke to bit.bio's Dr. Farah Patell-Socha and Furqan Iqbal.

In this opinion piece, Eric Rhodes, CEO of ERS Genomics, shares his roundup of some of the most exciting innovations in synthetic biology right now.

In this interview, we spoke to Rachel Marty Pyke PhD, manager of bioinformatics science at Personalis, to find out how machine learning can be used to detect genomic instability as a biomarker for cancer immunotherapy.

We spoke to Dr. Audrey Dubourg, product manager at CN Bio to find out more about how its organ-on-chip platform could bridge the gap between the current 2D models and animal models, providing human-relevant insights into diseases such as non-alcoholic steatohepatitis.

In this piece, Adam Clore explores how smart automation can help synthetic biology companies become more resilient.

To find out more about how early-stage funding could improve longevity research, we had the pleasure of speaking to Garri Zmudze, executive director of the Longevity Science Foundation.

Learn how automation can help to obtain high-quality next generation sequencing research data.